van der Graaf Y - Search Results

1

The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease.

Schrover IM, van der Graaf Y, Spiering W, Visseren FL; SMART study group. Schrover IM, et al. Among authors: van der graaf y. Eur J Prev Cardiol. 2018 Sep;25(14):1548-1557. doi: 10.1177/2047487318790722. Epub 2018 Jul 27. Eur J Prev Cardiol. 2018. PMID: 30052066 Free PMC article.

2

Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases.

Westerink J, van der Graaf Y, Faber DR, Spiering W, Visseren FL; SMART study group. Westerink J, et al. Among authors: van der graaf y. Eur J Prev Cardiol. 2012 Aug;19(4):864-73. doi: 10.1177/1741826711416045. Epub 2011 Jul 1. Eur J Prev Cardiol. 2012. PMID: 21724680

3

Prediction model with metabolic syndrome to predict recurrent vascular events in patients with clinically manifest vascular diseases.

Wassink AM, van der Graaf Y, Janssen KJ, Cook NR, Visseren FL; SMART Study Group. Wassink AM, et al. Among authors: van der graaf y. Eur J Prev Cardiol. 2012 Dec;19(6):1486-95. doi: 10.1177/1741826711426636. Epub 2011 Oct 18. Eur J Prev Cardiol. 2012. PMID: 22008749

4

Increased visceral adipose tissue is associated with increased resting heart rate in patients with manifest vascular disease.

Bemelmans RH, van der Graaf Y, Nathoe HM, Wassink AM, Vernooij JW, Spiering W, Visseren FL; SMART Study Group. Bemelmans RH, et al. Among authors: van der graaf y. Obesity (Silver Spring). 2012 Apr;20(4):834-41. doi: 10.1038/oby.2011.321. Epub 2011 Oct 20. Obesity (Silver Spring). 2012. PMID: 22016101 Free article.

5

Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART study.

Verhagen SN, Wassink AM, van der Graaf Y, Gorter PM, Visseren FL; SMART Study Group. Verhagen SN, et al. Among authors: van der graaf y. Cardiovasc Diabetol. 2011 Nov 21;10:100. doi: 10.1186/1475-2840-10-100. Cardiovasc Diabetol. 2011. PMID: 22098712 Free PMC article.

6

Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or nonHDL-cholesterol.

van de Woestijne AP, Wassink AM, Monajemi H, Liem AH, Nathoe HM, van der Graaf Y, Visseren FL; SMART study group. van de Woestijne AP, et al. Among authors: van der graaf y. Int J Cardiol. 2013 Jul 31;167(2):403-8. doi: 10.1016/j.ijcard.2012.01.008. Epub 2012 Jan 21. Int J Cardiol. 2013. PMID: 22265582 Free article.

7

Risk of elevated resting heart rate on the development of type 2 diabetes in patients with clinically manifest vascular diseases.

Bemelmans RH, Wassink AM, van der Graaf Y, Nathoe HM, Vernooij JW, Spiering W, Visseren FL; SMART Study Group. Bemelmans RH, et al. Among authors: van der graaf y. Eur J Endocrinol. 2012 Apr;166(4):717-25. doi: 10.1530/EJE-11-1017. Epub 2012 Jan 27. Eur J Endocrinol. 2012. PMID: 22285702

8

The prevalence of obesity-related hypertension and risk for new vascular events in patients with vascular diseases.

Vernooij JW, van der Graaf Y, Visseren FL, Spiering W; SMART study group. Vernooij JW, et al. Among authors: van der graaf y. Obesity (Silver Spring). 2012 Oct;20(10):2118-23. doi: 10.1038/oby.2012.76. Epub 2012 Mar 26. Obesity (Silver Spring). 2012. PMID: 22517513 Free article.

9

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.

Lafeber M, Grobbee DE, Spiering W, van der Graaf Y, Bots ML, Visseren FL; SMART Study Group. Lafeber M, et al. Among authors: van der graaf y. Eur J Prev Cardiol. 2013 Oct;20(5):771-8. doi: 10.1177/2047487312449587. Epub 2012 May 30. Eur J Prev Cardiol. 2013. PMID: 22649123

10

Relation between adiposity and hypertension persists after onset of clinically manifest arterial disease.

Dorresteijn JA, Spiering W, Van Der Graaf Y, Visseren FL; SMART Study Group. Dorresteijn JA, et al. Among authors: van der graaf y. J Hypertens. 2012 Dec;30(12):2331-7. doi: 10.1097/HJH.0b013e328357f18a. J Hypertens. 2012. PMID: 23041751

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

641 results

Search Page

Filters